Henagliflozin in Patients With Atrial Fibrillation
Status:
Not yet recruiting
Trial end date:
2023-05-31
Target enrollment:
Participant gender:
Summary
The HENA-AF trial will evaluate the effects of henagliflozin on cardiac structure, function,
and biomarkers of HF in patients with AF. Participants with persistent AF, enlarged left
atrium, and at least another cardiovascular risk factor will be randomized to henagliflozin
or placebo. Cardiac MRI will be performed at baseline and at 6 months to measure the changes
in cardiac structure and function. The primary hypothesis is that henagliflozin will reduce
the left atrial volume index at 6 months in patients with AF.